MX2024002674A - Derivados de tiadiazolona utiles como activadores de ampk. - Google Patents

Derivados de tiadiazolona utiles como activadores de ampk.

Info

Publication number
MX2024002674A
MX2024002674A MX2024002674A MX2024002674A MX2024002674A MX 2024002674 A MX2024002674 A MX 2024002674A MX 2024002674 A MX2024002674 A MX 2024002674A MX 2024002674 A MX2024002674 A MX 2024002674A MX 2024002674 A MX2024002674 A MX 2024002674A
Authority
MX
Mexico
Prior art keywords
sup
thiadiazolone
derivatives useful
ampk activator
ampk
Prior art date
Application number
MX2024002674A
Other languages
English (en)
Spanish (es)
Inventor
Jacob Westman
Thomas Edlund
Original Assignee
Betagenon Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagenon Ab filed Critical Betagenon Ab
Publication of MX2024002674A publication Critical patent/MX2024002674A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Peptides Or Proteins (AREA)
MX2024002674A 2021-09-02 2022-09-01 Derivados de tiadiazolona utiles como activadores de ampk. MX2024002674A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2112529.9A GB202112529D0 (en) 2021-09-02 2021-09-02 New compounds
PCT/GB2022/052234 WO2023031609A1 (en) 2021-09-02 2022-09-01 Thiadiazolone derivatives useful as ampk activator

Publications (1)

Publication Number Publication Date
MX2024002674A true MX2024002674A (es) 2024-03-19

Family

ID=78076730

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002674A MX2024002674A (es) 2021-09-02 2022-09-01 Derivados de tiadiazolona utiles como activadores de ampk.

Country Status (11)

Country Link
US (1) US20250136563A1 (enExample)
EP (1) EP4396171A1 (enExample)
JP (1) JP2024535745A (enExample)
KR (1) KR20240055039A (enExample)
CN (1) CN118510762A (enExample)
AU (1) AU2022336441A1 (enExample)
CA (1) CA3230307A1 (enExample)
GB (1) GB202112529D0 (enExample)
IL (1) IL310871A (enExample)
MX (1) MX2024002674A (enExample)
WO (1) WO2023031609A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3075388T3 (en) 2019-10-18 2026-08-04 Betagenon Ab New formulations
GB202015585D0 (en) 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
WO2025252672A1 (en) * 2024-06-03 2025-12-11 Betagenon Ab Use of tryptophan and metabolites thereof as biomarkers for treatment methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200720264A (en) * 2005-04-25 2007-06-01 Lundbeck & Co As H Pro-drugs of n-thiazol-2-yl-benzamide derivatives
US20090156644A1 (en) * 2005-07-21 2009-06-18 Jacob Westman Use of thiazole derivatives and analogues in the treatment of cancer
AU2010270030B2 (en) * 2009-07-08 2015-12-24 Baltic Bio Ab 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
JP2013230986A (ja) * 2010-08-25 2013-11-14 Kyorin Pharmaceutical Co Ltd 新規ヒダントイン誘導体及びそれらを有効成分とする医薬
KR101889993B1 (ko) * 2010-09-10 2018-08-20 시오노기세야쿠 가부시키가이샤 Ampk 활성화 작용을 갖는 헤테로환 축합 이미다졸 유도체
WO2013108026A1 (en) * 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
CN111848579B (zh) * 2019-04-26 2023-11-14 君实润佳(上海)医药科技有限公司 4-(2,6-二氯苯甲酰氨基)-n-(4-哌啶基)-1h-吡唑-3-甲酰胺的前药
GB202015585D0 (en) * 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds

Also Published As

Publication number Publication date
US20250136563A1 (en) 2025-05-01
IL310871A (en) 2024-04-01
EP4396171A1 (en) 2024-07-10
CA3230307A1 (en) 2023-03-09
AU2022336441A1 (en) 2024-03-07
WO2023031609A1 (en) 2023-03-09
CN118510762A (zh) 2024-08-16
JP2024535745A (ja) 2024-10-02
KR20240055039A (ko) 2024-04-26
GB202112529D0 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
MX2023001379A (es) Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a.
CR20240147A (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
MX2025000642A (es) Compuestos macrociclicos para el tratamiento de cancer
ZA202409114B (en) MODULATORS OF THR-ß AND METHODS OF USE THEREOF
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
TW200833675A (en) Nicotinamide derivatives
MX2024000299A (es) Compuestos antivirales.
EP4252848A3 (en) Oxysterols and methods of use thereof
TW200728307A (en) Novel spirochromanone derivatives
MX2010007375A (es) Nuevos derivados de lupano.
MX2023010909A (es) Derivados de purina como agentes anticancerigenos.
TW200612958A (en) Substituted imidazole derivatives
NZ600207A (en) Substituted 4-aminocyclohexane derivatives
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
EP4360707A3 (en) Compositions for treating spinal muscular atrophy
PH12022550175A1 (en) Macrocyclic compounds as sting agonists and methods and uses thereof
MX2025010357A (es) Degradador de irak4, y uso del mismo
MX2025010256A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
PH12021552513A1 (en) Pyrrole compounds
MX2013002620A (es) Novedosas n-hidroxi-benzamidas para el tratamiento del cancer.
MX2024003645A (es) Derivados de piridinilacetamida como activadores de canales de sodio.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2020008746A (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
MY158069A (en) Tricyclic compound and pharmaceutical use thereof
MX2024012967A (es) Derivados de piridina para el tratamiento de los trastornos psiquiatricos